Skip to content

The Predictive and Diagnostic Value of Cystatin C and High Sensitive Troponin

The Predictive and Diagnostic Value of Using Cystatin C and High Sensitive Troponin Level Together for Diagnosis of ACS in Patients With Chronic Kidney Disease Coming to Emergency Department With Chest Pain

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05303441
Enrollment
172
Registered
2022-03-31
Start date
2022-03-07
Completion date
2023-02-01
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Chronic Kidney Diseases

Brief summary

Our study is planning to evaluate patients with chronic kidney disease who come to the emergency department with chest pain. Estimated GFR (cisGFR) with cystatin and estimated GFR (creaGFR) with creatinine will be calculated. Symptoms, ECG and troponin values of patients will be evaluated for diagnosis of acute coronary syndrome

Detailed description

Our study is planning to evaluate patients with chronic kidney disease who come to the emergency department with chest pain. Estimated GFR (cisGFR) with cystatin and estimated GFR (creaGFR) with creatinine will be calculated. Symptoms, ECG and troponin values of patients will be evaluated for diagnosis of acute coronary syndrome and the final diagnosis of AMI will be adjudicated by 2 independent cardiologists.Serial troponin measurements and eGFR values will be proportioned. These values the will be evaluated and compared for patients with acute coronary syndrome(culprit lesion on conventional coronary angiography) and non-ACS ones . With these data we aim to facilitate the diagnosis of acute coronary syndrome,increase the specificity and sensitivity of cardiac troponins for the diagnosis of acute coronary syndrome of patients with chronic kidney disease, increase the utility of high sensitive troponins for patients with chronic kidney disease. Again, with these data, it is aimed to reduce the number of false negative and false positive diagnosis of acute coronary syndrome .

Interventions

PROCEDUREpercutaneous coronary intervention

conventional coronary angiography

Sponsors

Ankara Diskapi Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age over 18, 2. chronic kidney diease having chest pain or equivalent of chest pain (dyspnea, diaphoresis, syncope, nausea, vomiting) -

Exclusion criteria

1. STEMI, 2. age less than 18, 3. missing data, 4. patients referred to or accepted from another medical facility

Design outcomes

Primary

MeasureTime frameDescription
anticipated ACStime passed until PCI (percutaneous coronary intervention) (pre-intervention) or admission to hospitalThe role of cystatin C in diagnosis acute coronary syndrome when used with troponin in patients with chronic renal failure.
exclusion of acstime passed during emergency department visit until discharge avarage of 3-6 hoursexclusion of ACS according to current guidelines

Countries

Turkey (Türkiye)

Contacts

Primary Contactbedriye müge sönmez, assoc. prof.
mugesonmez06@yahoo.com+903125962470
Backup Contactelif hamzaçebioğlu, resident
turkuaz-61@windowslive.com+903125962469

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026